

Unità Ematologia e Trapianti

IRCCS IRST "Dino Amadori" Meldola presenta

THE LYMPHOMAS CONFERENCE 3rd EDITION

ROMA 08-09 MAGGIO 2026

A.Roma Italian Lifestyle hotel

President: Gerardo Musuraca Nicola Normanno

Scientific secretariat:

Claudio Cerchione, Eliana Liardo, Alessandro Lucchesi, Francesco Malaspina, Giovanni Martinelli,
Margherita Parolini, Costantino Riemma, Pietro Rossi, Jessica Rosa

DAY 1 8th May

Registration: 8:30

Welcome and introduction: Gerardo Musuraca, Nicola Normanno

09:00 SESSION 1

The biology of the Diffuse Large B cell Lymphoma

Chairs: Gerardo Musuraca and Giovanni Martinelli

-The pathways of Diffuse large B-cell lymphomas (DLBCL): Classifications and artificial intelligence to understand the "enemy"

Louis Staudt 09:00-09:20

-What we know about the genetics of diffuse large cell lymphoma and how it makes it work

Riccardo dalla Favera 09:20-09:40

- Microenvironment and interaction with genetics in controlling DLBCL development and resistance

Laura Pasqualucci 09:40-10:00

"Rumble in the jungle" 10:00-10:10

Which are the best drivers? Suggestions for future therapies

L.Staudt, L. Pasqualucci, R. Dalla Favera, G. Martinelli, G. Musuraca

10:10 SESSION 2

Diffuse Large B cell Lymphoma: Treatment strategies PART A

Chairs: Umberto Vitolo, Greg Nowakoski, Claudio Cerchione

-Biology driven or agnostic: The Multiverse in the first line of DLBCL

Grzegorz Nowakowski 10:10-10:30

-Relapsed/refractory: The CAR T way and the current landscape of cellular therapies

Stephen Schuster 10:30-10:50

-Relapsed/refractory: Looking for the best sequencing or salvage strategy (Bispecifics, Drug conjugates and friends)

Gerardo Musuraca 10:50-11:20

-Relapsed/refractory LBCL: The evolution of the CAR T cells: Allo, NK, bi or trispecific

Lapo Alinari 11:20-11:40

Coffe Break 11:40-11:50

Diffuse Large B cell lymphoma: Treatment strategies PART B

Chairs: Stefan Hohaus, Patrizia Tosi, Mark Roschewski

-High Grade Lymphomas

Grzegorz Nowakowski 11:50-12:10

-Next strategies and molecules on the window

Umberto Vitolo 12:10-12:30

-ctDNA in Large B cell Lymphoma

Mark Roschewski 12:30-12:50

-Artificial intelligence in the DLBCL “Instructions for use “ to build future treatments of DLBCL

Francesco Malaspina 12:50-13:10

13.10-14.10 Lunch

Symposium NO ECM – Sponsored by Abbvie

Chair: Gerardo Musuraca

Learning from italian experience: from the speed of action to the management of patients with epcoritamab in R/R NHL - Francesco Piazza 13:10-13:30

Discussion

13:30-13:35

14.10 SESSION 3

Hodgkin Lymphoma

Chairs: Antonello Pinto, Anna Sureda

-The biology of Hodgkin Lymphoma

Ralf Koppers 14:10-14:30

-First-line treatment in Hodgkin lymphoma: The evolving landscape

Antonello Pinto 14:30-14:50

-Relapsed/refractory HL: Salvage treatments strategies: All you need to know about transplant and new drugs

Anna Sureda 14:50- 15:20

“Rumble in the jungle” 15:20-15:30

The wind of change in Hodgkin Lymphoma

A. Sureda, A. Pinto, R. Koppers

Coffee break 15:30-15:50

15:50 SESSIONE 4

Mantle cell lymphoma

Chairs: Enrico Derenzini, Kami Maddocks

-Lecture: From the biology to target cure. A risk based approach in the Front line strategies

Kami Maddocks 15:50-16:20

-Salvage treatments in relapsed or refractory patients: Now and beyond

Elisabeth Silkenstedt 16:20-16:40

-CAR T cells in MCL: Current landscape and future prospectives

Lapo Alinari 16:40-17:00

“Rumble in the jungle” 17:00-17:10

What we have ahead in mantle cell lymphoma

K. Maddocks, E.Silkenstedt, L. Alinari, E. Derenzini

17:10 SESSION 5

Marginal Zone Lymphoma and Waldenstrom Macroglobulinemia

Chairs: Emanuele Zucca , Davide Rossi

-Marginal zone Lymphoma: A particular journey from the biology to the clinic in first line.

Davide Rossi 17:10-17:30

-Marginal zone lymphoma: From the failure of the front line to the next future

Emanuele Zucca 17:30-17:50

-Waldenstrom Macroglobulinemia: From diagnosis to therapy: What we have learned and what lies ahead

Steven Treon 17:50-18:20

Chair: Francesco Lanza

Lecture: Allotransplant in Lymphoma: Who, when and How? Update in 2025 in the era of cell therapies and new drugs

Antonio Pierini 18:20-18:50

Closing day remarks 18:50

DAY 2 9th May

8:50 SESSION 6

Follicular lymphoma

Chairs: Alessandro Pulsoni, Alessandro Lucchesi

-Genetic and Epigenetic of transformation in Follicular lymphoma

Laura Pasqualucci 08:50-09:10

- First line therapy: State of the art and state of the future

Stefano Luminari 09:10-09:30

-Relapse/refractory disease before and beyond CAR T

Pietro Rossi 09:30-09:50

-CAR T cell: Is there a role in follicular lymphoma instead of other compounds?

Stephen Schuster 09:50- 10:10

10:10-11:05 Coffee Break Symposia NO ECM

Chair: Gerardo Musuraca

Sponsored by Abbvie

Sailing through the bcl2 inhibition pathway

V+X: venetoclax as the backbone therapy in 1L and R/R CLL

Gianluca Gaidano 10:10-10:30

Discussion

10:30-10:35

Sponsored by Lilly

Translating Novel BTK Inhibition into Clinical Decisions

Treatment Guidelines and Clinical Efficacy of Pirtobrutinib: Evidence from the BRUIN-

CLL-321 Antonio Cuneo 10:35-10:50

Clinical Practice: A Case-Based Discussion in Relapsed/Refractory CLL

Enrico Derenzini 10:50-11:00

Discussion

11:00-11:05

11:05 SESSION 7

Chronic Lymphocytic Leukemia

Chairs: Luca Laurenti

- The biology that leads to treatment: Why the drugs work in CLL

Gianluca Gaidano 11:05-11:25

- The right treatment in the right patient: Which first-line and why? **Lydia Scarfo' 11:25-11:45**

What we have to use and when, if we fail in CLL

Talha Munir 11:45-12:05

12.05 SESSION 8

Special types of lymphomas

Chairs: Maurizio Martelli, Christina Cox

-T-cell lymphomas: From the biology to the treatments

Enrico Derenzini 12.05-12:25

- Primary CNS Lymphoma: Everything you need to know

Andres Ferreri 12:25-12:50

-Primary Mediastinal Diffuse large B cell lymphoma: Do we know what the best strategy is to treat it?

Maurizio Martelli 12:50-13:10

-Burkitt Lymphoma: To know and tame the monster

Mark Roschewski 13:10-13:30

-Primary cutaneous lymphomas

Alessandro Pileri 13:30-13:50

Closing Remarks 13:50 "See you next year !"

Gerardo Musuraca, Nicola Normanno

Lunch box 13:50

Rationale

Lymphoid malignancies represent one of the most biologically heterogeneous and therapeutically dynamic areas in modern hematology. Over the last decade, major advances in genomics, tumor microenvironment characterization, immune biology, and translational research have profoundly reshaped the classification, prognosis, and treatment of lymphomas. At the same time, the rapid expansion of novel therapeutic strategies—including targeted agents, antibody–drug conjugates, bispecific antibodies, and cellular therapies—has introduced unprecedented opportunities, but also significant clinical and strategic challenges.

The Lymphomas Conference – 3rd Edition is conceived as an international, high-level scientific forum aimed at integrating **biological insights with clinical decision-making**, fostering a comprehensive and forward-looking discussion on both common and rare lymphoid malignancies. The meeting brings together leading basic scientists, translational researchers, and clinicians to critically analyze how molecular biology, genetics, epigenetics, immune interactions, and artificial intelligence are redefining disease understanding and therapeutic paradigms.

A central focus of the conference is **Diffuse Large B-Cell Lymphoma (DLBCL)**, used as a model to illustrate the transition from biologically driven classification to precision treatment strategies, including optimal sequencing of immunochemotherapy, bispecific antibodies, CAR T-cell therapies, and emerging cellular platforms.

Similar integrative approaches are extended to Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia, and special lymphoma entities, addressing both frontline and relapsed/refractory settings.

Special attention is devoted to **unmet clinical needs**, such as the management of elderly and frail patients, high-grade and transformed lymphomas, resistance mechanisms, minimal residual disease monitoring through circulating tumor DNA, and the evolving role of allogeneic transplantation in the era of immune and cellular therapies.

Through interactive sessions, expert panels, and multidisciplinary discussions, the conference aims to:

- Bridge the gap between biological discovery and clinical practice
- Promote critical evaluation of emerging therapies and treatment algorithms
- Encourage rational sequencing and personalization of care
- Stimulate collaboration among international experts across disciplines

Ultimately, **The Lymphomas Conference – 3rd Edition** seeks to provide participants with a **clear, evidence-based, and future-oriented framework** to improve outcomes and quality of care for patients with lymphoid malignancies in an increasingly complex therapeutic landscape.



ACRONIMI:

DLBCL - Diffuse large B-cell lymphomas
CAR T - Chimeric Antigen Receptor T-cell
NK - Natural Killer
HL - Hodgkin's Lymphoma
MCL - Mantle Cell Lymphoma
CLL - Chronic Lymphocytic Leukemia
CNS - Central Nervous System

ProEventi srl P.IVA: 03572430712 | SDI: M5UXCR1 |
Sede Legale : V.le Matteotti 36, San Severo (FG) 71016 – 0882.242151
BigBo - Via della Ferriera 4, Bologna (BO) 40133

info@proeventi.it | www.proeventi.it | promoterineventisrl@pec.it |

